Indolent Lymphoma-Pipeline Review, H2 2015

Indolent Lymphoma-Pipeline Review, H2 2015

  • Products Id :- GMDHC6983IDB
  • |
  • Pages: 183
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Indolent Lymphoma-Pipeline Review, H2 2015


Global Markets Direct's, 'Indolent Lymphoma-Pipeline Review, H2 2015', provides an overview of the Indolent Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Indolent Lymphoma Overview 9

Therapeutics Development 10

Pipeline Products for Indolent Lymphoma-Overview 10

Pipeline Products for Indolent Lymphoma-Comparative Analysis 11

Indolent Lymphoma-Therapeutics under Development by Companies 12

Indolent Lymphoma-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Indolent Lymphoma-Products under Development by Companies 15

Indolent Lymphoma-Companies Involved in Therapeutics Development 17

AbbVie Inc. 17

Altor BioScience Corporation 18

Astellas Pharma Inc. 19

Bayer AG 20

Biothera, Inc. 21

Boehringer Ingelheim GmbH 22

Celgene Corporation 23

F. Hoffmann-La Roche Ltd. 24

Gilead Sciences, Inc. 25

Incyte Corporation 26

Infinity Pharmaceuticals, Inc. 27

Juno Therapeutics Inc. 28

Kite Pharma, Inc. 29

MedImmune, LLC 30

Merck & Co., Inc. 31

Merck KGaA 32

MorphoSys AG 33

Indolent Lymphoma-Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Combination Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

acalisib-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

ALT-803-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

bendamustine hydrochloride-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

BI-836826-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

CC-122-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

copanlisib hydrochloride-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

DI-B4-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

duvelisib-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

entospletinib-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ibrutinib-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

idelalisib-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Imprime PGG-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

INCB-39110-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

INCB-40093-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

INCB-50465-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

JCAR-015-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

KTE-C19-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

lenalidomide-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

MEDI-0680-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

MEDI-551-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

MEDI-551 + MEDI-0680-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

MOR-208-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

obinutuzumab-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

venetoclax-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

vorinostat-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Indolent Lymphoma-Recent Pipeline Updates 104

Indolent Lymphoma-Dormant Projects 168

Indolent Lymphoma-Discontinued Products 169

Indolent Lymphoma-Product Development Milestones 170

Featured News & Press Releases 170

Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 170

Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 170

Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 171

Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 172

Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 173

Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 175

Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 176

Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 177

Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 178

Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 180

Appendix 182

Methodology 182

Coverage 182

Secondary Research 182

Primary Research 182

Expert Panel Validation 182

Contact Us 182

Disclaimer 183

List of Tables

Number of Products under Development for Indolent Lymphoma, H2 2015 10

Number of Products under Development for Indolent Lymphoma-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Products under Development by Companies, H2 2015 (Contd..1) 16

Indolent Lymphoma-Pipeline by AbbVie Inc., H2 2015 17

Indolent Lymphoma-Pipeline by Altor BioScience Corporation, H2 2015 18

Indolent Lymphoma-Pipeline by Astellas Pharma Inc., H2 2015 19

Indolent Lymphoma-Pipeline by Bayer AG, H2 2015 20

Indolent Lymphoma-Pipeline by Biothera, Inc., H2 2015 21

Indolent Lymphoma-Pipeline by Boehringer Ingelheim GmbH, H2 2015 22

Indolent Lymphoma-Pipeline by Celgene Corporation, H2 2015 23

Indolent Lymphoma-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 24

Indolent Lymphoma-Pipeline by Gilead Sciences, Inc., H2 2015 25

Indolent Lymphoma-Pipeline by Incyte Corporation, H2 2015 26

Indolent Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 27

Indolent Lymphoma-Pipeline by Juno Therapeutics Inc., H2 2015 28

Indolent Lymphoma-Pipeline by Kite Pharma, Inc., H2 2015 29

Indolent Lymphoma-Pipeline by MedImmune, LLC, H2 2015 30

Indolent Lymphoma-Pipeline by Merck & Co., Inc., H2 2015 31

Indolent Lymphoma-Pipeline by Merck KGaA, H2 2015 32

Indolent Lymphoma-Pipeline by MorphoSys AG, H2 2015 33

Assessment by Monotherapy Products, H2 2015 34

Assessment by Combination Products, H2 2015 35

Number of Products by Stage and Target, H2 2015 37

Number of Products by Stage and Mechanism of Action, H2 2015 39

Number of Products by Stage and Route of Administration, H2 2015 41

Number of Products by Stage and Molecule Type, H2 2015 43

Indolent Lymphoma Therapeutics-Recent Pipeline Updates, H2 2015 104

Indolent Lymphoma-Dormant Projects, H2 2015 168

Indolent Lymphoma-Discontinued Products, H2 2015 169

List of Figures

Number of Products under Development for Indolent Lymphoma, H2 2015 10

Number of Products under Development for Indolent Lymphoma-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 14

Assessment by Monotherapy Products, H2 2015 34

Number of Products by Top 10 Targets, H2 2015 36

Number of Products by Stage and Top 10 Targets, H2 2015 36

Number of Products by Top 10 Mechanism of Actions, H2 2015 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 38

Number of Products by Top 10 Routes of Administration, H2 2015 40

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 40

Number of Products by Top 10 Molecule Types, H2 2015 42

Number of Products by Stage and Top 10 Molecule Types, H2 2015 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbbVie Inc.

Altor BioScience Corporation

Astellas Pharma Inc.

Bayer AG

Biothera, Inc.

Boehringer Ingelheim GmbH

Celgene Corporation

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

Kite Pharma, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

MorphoSys AG

Indolent Lymphoma Therapeutic Products under Development, Key Players in Indolent Lymphoma Therapeutics, Indolent Lymphoma Pipeline Overview, Indolent Lymphoma Pipeline, Indolent Lymphoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]